1. Cardiac noradrenergic deficiency revealed by [sup.18]F-dopamine positron emission tomography identifies preclinical central Lewy body diseases
- Author
-
Goldstein, David S., Holmes, Courtney, Sullivan, Patti, Lopez, Grisel, Gelsomino, Janna, Moore, Sarah, Isonaka, Risa, Wu, Tianxia, and Sharabi, Yehonatan
- Subjects
Diagnosis ,Care and treatment ,Analysis ,Genetic aspects ,Patient outcomes ,Health aspects ,Positron emission tomography -- Analysis ,Aging (Biology) -- Health aspects ,Sympathectomy -- Patient outcomes ,Lewy body disease -- Diagnosis -- Care and treatment -- Genetic aspects ,Aging -- Health aspects ,PET imaging -- Analysis - Abstract
Introduction Aging-related neurodegenerative diseases are posing an increasing public health burden as populations are getting older. Prominent among these conditions are the central Lewy body diseases (LBDs), Parkinson disease (PD), [...], BACKGROUND. In Lewy body diseases (LBDs) Parkinson disease (PD), and dementia with Lewy bodies (DLB), by the time parkinsonism or cognitive dysfunction manifests clinically, substantial neurodegeneration has already occurred. Biomarkers are needed to identify central LBDs in a preclinical phase, when neurorescue strategies might forestall symptomatic disease. This phase may involve catecholamine deficiency in the autonomic nervous system. We analyzed data from the prospective, observational, long-term PDRisk study to assess the predictive value of low versus normal cardiac [sup.18]F-dopamine positron emission tomography (PET), an index of myocardial content of the sympathetic neurotransmitter norepinephrine, in at-risk individuals. METHODS. Participants self-reported risk factor information (genetics, olfactory dysfunction, dream enactment behavior, and orthostatic intolerance or hypotension) at a protocol-specific website. Thirty-four with 3 or more confirmed risk factors underwent serial cardiac [sup.18]F-dopamine PET at 1.5-year intervals for up to 7.5 years or until PD was diagnosed. RESULTS. Nine participants had low initial myocardial [sup.18]F-dopamine-derived radioactivity ( CONCLUSION. Cardiac [sup.18]F-dopamine PET highly efficiently distinguishes at- risk individuals who are diagnosed subsequently with a central LBD from those who are not. TRIAL REGISTRATION. ClinicalTrials.gov NCT00775853. FUNDING. Division of Intramural Research, NIH, NINDS.
- Published
- 2024
- Full Text
- View/download PDF